Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic

First Antibody Therapy EUA

Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate. 

Eli Lilly
Lilly is the first to gain an EUA for its antibody therapy, but Regeneron looks likely to be not far behind.

Lilly's monoclonal antibody therapy bamlanivimab has been granted Emergency Use Authorization in the US for recently diagnosed, mild-to-moderate COVID-19 in high-risk patients.

The decision by the US Food and Drug Administration makes Lilly the first to bring an antibody therapy to patients,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip